In this season of harvesting joy and happiness, the launch of 奥维平® , with generic name of Oseltamivir Phosphate for Oral Suspension, was held in Shenzhen with great expectation. Experts, scholars, cooperative suppliers, agents and investors from all over the world gathered together to witness the exciting moment of the launch of 奥维平®.

奥维平®，Oseltamivir Phosphate for Oral Suspension，formally approved on October 26 in 2021. This product is indicated for the treatment and prevention of acute, uncomplicated influenza A and B in children above 2 weeks of age and older. It is the first Oseltamivir approved for use in people over 14 days of age and the first Oseltamivir Phosphate for Oral Suspension approved in China.

We are honored to invite three renowned experts in the field of pediatrics in China to the conference: Professor Yang Yonghong, a famous expert in pediatric infectious diseases; Professor Shen Kunling, an honorary chairman of the Pediatrics Branch of the Chinese Medical Association; Professor Zheng Yuejie, director of the Respiratory Department of Shenzhen Children's Hospital. All three experts expressed their congratulations on the launch of the new product, their recognition of the efforts made by Bemei Pharma in the field of pediatric medicine, and their wishes for a bright future for Bemei.

Professor Yang Yonghong affirmed the dosage form advantages of Oseltamivir Phosphate for Oral Suspension, "It's great to have such a product approved for children one month or even ten days old, expanding the age of use, which is a blessing for the prevention and treatment of influenza in children."

" Every year in influenza peak season, the incidence of seasonal influenza and childhood influenza infection in children is extremely high. A new dosage form such as Oseltamivir Phosphate for Oral Suspension, equipped with more accurate dispenser and good taste, can not only make children's medication more accurate and convenient, but also alleviate the difficulties of medication for underage children to a greater extent", said Professor Shen Kunling.

Professor Zheng Yuejie said, "This new dosage form is a solution to the problem of over-specification of Oseltamivir phosphate preparation, which provides a better basis for rational clinical use and will be welcomed by the majorities of doctors. I believe that the launch of this product will benefit more children, especially the infants, welcomed by the majorities of families."

Dr. B. Partha Saradhi Reddy, Chairman of Hetero Group, India, and Mr. Murali Variyath, General Manager of Beijing Company, recorded a video from Hyderabad to celebrate the occasion. Both Dr. B. Reddy and Mr. Murali said, "It is a great pleasure to have a strong and groundbreaking partnership with Bemei Pharma in China, and we thank Bemei for its efforts in achieving this significant achievement and look forward to conquering more milestones with Bemei."

Mr. Lin Xuewu, an agent from Fujian Province, said: “The national policy of the medical industry has allowed manufacturers and agents to have a closer relationship. Based on the trust in Ms. Wu and the recognition of Beimei, I have chosen to become one of Beimei’s agents and also I am very looking forward to and optimistic about Beimei's follow-up product line and hope to achieve long-term and win-win cooperation with Beimei Pharma."

Mr. Ouyang Yiping, President of Xinhao Investment Group, once again affirmed the unremitting efforts made by Bemei for the approval of the product, and he said, "Adhering to quality and credibility, Bemei is a trustworthy partner who does what it says. Bemei has responded to the historical opportunity of the development of pediatric medicine and has been nourished in all aspects in the hot soil of Shenzhen to break through the ground and take off, at the same time Bemei has a professional and competent team, which will surely bring pediatric medicine to a new height. Xinhao and other partners will also continue to support Bemei as always."

Ms. Wu Guangmei, President of Bemei Pharmaceuticals, once again expressed her gratitude to our partner Hetero, investors, and agents nationwide for their trust and support to Bemei, as well as to our team for their hard work and diligent efforts during the whole process of project establishing, signing, filing, and getting approval for the 奥维平®，Oseltamivir Phosphate for Oral Suspension project.

Ms. Wu also took this opportunity to introduce a series of products to be launched by Bemei one by one, and shared Bemei' efforts and breakthroughs in the direction of innovation as well as the plan of Bemei Pediatric Drug R&D Center which is currently under application. The Beimei team led by Ms. Wu insists on making real high quality, full series, and safe pediatric drugs, and to be the innovator and explorer in the field of pediatric drugs. Without forgetting the original heart, move forward bravely, the future of Beimei is promising!

With great excitement, Ms. Wu and the guests lighted up the launch pad, officially opening and celebrating the launch of 奥维平®. 奥维平® will bring new treatment options for influenza patients, especially for children with influenza, which can target the clinical needs that the existing dosage forms cannot meet and benefit the majority of children and families.

The launch of Oseltamivir Phosphate for Oral Suspension finished successfully!